Status: Recruiting
Study of Ravulizumab in Pediatric Participants With Primary IgAN
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.
Participants needed: 24
Trial details
Phase: Phase 3Age: 2-18Biological sex: AllType: InterventionalSponsor: Alexion Pharmaceuticals, Inc.Updated: Mar 17, 2026Locations: 14
Eligibility criteria
Participant must be 2 to < 18 years of age at the time of signing the informed c... [+7]
Diagnosis of rapidly progressive glomerulonephritis [+13]